Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare

被引:33
作者
Cooper, WO
Hickson, GB
Ray, WA
机构
[1] Vanderbilt Univ, Sch Med, Div Gen Pediat, Dept Pediat, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Prevent Med, Div Pharmacoepidemiol, Nashville, TN 37232 USA
关键词
D O I
10.1111/j.1365-3016.2003.00542.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 [公共卫生与预防医学]; 120402 [社会医学与卫生事业管理];
摘要
Filling of prescriptions for medications labelled as category X by the United States Food and Drug Administration (considered to be contraindicated for use in pregnancy) was identified among 95 284 women enrolled in TennCare, Tennessee's programme for Medicaid enrollees and individuals without health insurance. Using administrative claims data, 391 women (4.10/1000) were identified as having filled category X prescriptions during pregnancy. This included 118 women (1.24/1000) who filled prescriptions for non-contraceptive oestrogens, 81 (0.85/1000) for sedatives, and 71 (0.75/1000) for statins. While many women had physician visits with a diagnosis consistent with a possible indication for an individual drug outside of pregnancy, none of these indications is included for use during pregnancy. Older women and disabled women were more likely than younger women (P < 0.0001) and women enrolled for other reasons (P < 0.0001) to fill category X prescriptions. Nearly two-thirds of the 391 women filled prescriptions after clinical signs or pregnancy tests would indicate pregnancy; nearly 40% filled a category X prescription after a pregnancy-related physician visit. Although the absolute rate of category X medication use in pregnancy is low, substantial numbers of women and their fetuses are exposed during pregnancy. Women above the age of 35 years and women enrolled in TennCare because of disabilities were more likely to fill prescriptions for category X medications during pregnancy than others, implying that risk communication to practitioners and women should focus on identification of these women to reduce their risk of exposure.
引用
收藏
页码:106 / 111
页数:6
相关论文
共 22 条
[1]
[Anonymous], 1997, PHYS DESK REF, P1723
[2]
Briggs G., 1998, DRUGS PREGNANCY LACT, V5th
[3]
Briggs GG., 2008, DRUGS PREGNANCY LACT, P431
[4]
Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis [J].
Cooper, WO ;
Griffin, MR ;
Arbogast, P ;
Hickson, GB ;
Gautam, S ;
Ray, WA .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2002, 156 (07) :647-650
[5]
Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis [J].
Cooper, WO ;
Ray, WA ;
Griffin, MR .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (01) :101-106
[6]
New use of anticonvulsant medications among children enrolled in the Tennessee Medicaid program [J].
Cooper, WO ;
Federspiel, CF ;
Griffin, MR ;
Hickson, GB .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1997, 151 (12) :1242-1246
[7]
Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks? [J].
Doering, PL ;
Boothby, LA ;
Cheok, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (02) :333-339
[8]
FREEMAN RK, 1997, GUIDELINES PERINATAL
[9]
FRIEDMAN JM, 1990, OBSTET GYNECOL, V75, P594
[10]
Prescription of drugs during pregnancy in France [J].
Lacroix, I ;
Damase-Michel, C ;
Lapeyre-Mestre, M ;
Montastruc, J .
LANCET, 2000, 356 (9243) :1735-1736